Je li favipiravir koristan u liječenju osoba s COVID-19? Ključne poruke Zbog nedostatka čvrstih dokaza, nije jasno pruža li favipiravir bilo kakvu korist u liječenju osoba s infekcijom koronavirusom 2019 (COVID-19) kojima nije potreban bolnički prijem, kao i onih koji su primljeni u bolnicu. Favipiravir može uzrokovati blage nuspojave, ali ne čini se da uzrokuje velike ili ozbiljne nuspojave. Dosadašnje spoznaje Favipiravir je lijek za borbu protiv virusa. Obično se uzima na usta. Izvorno korišten za liječenje drugih virusnih infekcija, favipiravir je predložen kao potencijalni lijek za...

Koja je najbolja metoda za spašavanje zgrušanog hemodijaliznog pristupa? Ključne poruke • Nema dovoljno dokaza koji bi sugerirali da je određena intervencija bila bolja od druge za ishode neuspjeha pristupa, funkcioniranje nakon 30 dana, tehnički uspjeh i štetne događaje (i blaže i teške). • Kirurška trombektomija u usporedbi s mehaničkom trombektomijom može poboljšati funkciju pristupa nakon 30 dana; međutim, ti dokazi su vrlo nesigurni. • Smrt, disfunkcija pristupa, uspješna dijaliza i SONG (Standardizirani ishodi u nefrologiji) ishodi su bili rijetko prijavljeni. Zašto je važno liječiti...

Jesu li mobilne tehnologije korisne za povećanje dužine hodanja kod pacijenata s povremenom klaudikacijom? Ključne poruke Potrebna su velika, dobro osmišljena istraživanja mobilnih zdravstvenih (engl. mhealth) tehnologija za mjerenje udaljenosti koju osoba s povremenom klaudikacijom može hodati bez boli i maksimalnu udaljenost koju može hodati. Što su intermitentne (povremene) klaudikacije? Kod periferne arterijske bolesti (PAB), velike krvne žile nogu su sužene ili začepljene, što otežava dolazak kisika iz krvi do mišića kada je to potrebno. PAB može biti bez simptoma ili može uzrokovati...

Je li za liječenje visokog krvnog tlaka bolje uzimati lijekove za snižavanje krvnog tlaka ujutro ili navečer? Ključne poruke — Moguća je mala ili nikakva razlika u stopi smrtnosti iz bilo kojeg razloga u skupinama koje uzimaju lijekove za snižavanje krvnog tlaka ujutro ili navečer, ali nemamo povjerenja u te rezultate. Razlika u neželjenim učincima nije bila poznata. — Uzimanje lijekova za snižavanje krvnog tlaka navečer može dati nešto bolju kontrolu krvnog tlaka tijekom 24 sata nego njihovo davanje ujutro, ali nemamo povjerenja u ove rezultate. Što je visoki krvni tlak (hipertenzija)?...

Monday, February 12, 2024

Ublažavanje boli i nuspojave nove tehnike regionalne anestezije Ključne poruke Blokada područja erectora spinae (engl. erector spinae plane block, ESPB) vjerojatno ne ublažava intenzitet postoperativne boli 24 sata nakon operacije, ali se može izvršiti bez ozbiljnih neželjenih događaja te bi mogla smanjiti potrebu za oralnim analgeticima, kao i njihovim nuspojavama. Što je regionalna anestezija? Akutna postoperativna bol obično se liječi kombinacijom lijekova poput opioidnih lijekova s regionalnom anestezijom. Regionalna anestezija odnosi se na proces specifičnog umrtvljivanja živaca koji...

A new report jointly published by the AllTrials campaign, Cochrane Denmark, Cochrane Norway, Cochrane Sweden, the Dam Foundation, Melanomföreningen, and TranspariMED found that 475 clinical trials involving 83,903 patients completed during 2016-19 in Denmark, Iceland, Finland, Norway and Sweden have never made their results public in any form. This accounted for 22% of all clinical trial results across the five countries.

In cases where clinical trial results were made public, there was often a delay in publication. The report found that only 27% of all trials results were made public, in either registries or in journals, within 12 months. Within two years of study completion, only around half of the results were available to the public.

Not only is this lack of transparency in clinical trials a waste of increasingly scarce public funding, it harms patients and leaves gaps in medical evidence. This makes it very difficult to determine how safe and effective treatments actually are.

Nordic countries have recently changed regulations that require institutions to make the results of drug and device trials public on registries within 12 months of completion. While clinical trials which ended in the years prior to 2023 are not included in this legislation, both the Declaration of Helsinki and World Health Organization have clearly stated for years that the timely public sharing of results is an ethical obligation.

Matteo Bruschettini, Director of Cochrane Sweden, who co-authored the report, said:  “At Cochrane we highly value that findings of all studies become available. Otherwise, the synthesis of the evidence misses information thus resulting in misleading conclusions. This ultimately impacts the patients, clinicians and policy makers who need to make decisions based on a distorted picture of the evidence. This report should encourage initiatives to deal with this issue of medical research waste in the Nordic countries.”

The report calls for policy makers in Denmark, Iceland, Finland, Norway and Sweden to adopt national legislation requiring that the results of all clinical trials are made public and to set up monitoring mechanisms. It also calls for national medicines regulators and research funders to put in structures to prevent research waste and ensure that clinical trial results are made public. This is in line with WHO recommendations which urged ethics committees, regulatory authorities, professional bodies, sponsors, investigators, and funding agencies to act in their jurisdictions to ensure results from all clinical trials are reported and publicly disclosed.

The report has already received attention in Swedish media.

Cochrane will continue to advocate for improved clinical trial transparency, and will monitor progress in these countries with interest.

Thursday, February 8, 2024

Koji je najbolji prvi žičani luk u fiksnom ortodontskom aparatiću? Ključne poruke 1. Zbog ograničenih dokaza, još uvijek nije jasno je li neki materijal ili veličina žičanog luka bolja od drugog. 2. Postoji potreba za velikim, dobro planiranim istraživanjima. Nova istraživanja trebala bi mjeriti brzinu izravnavanja zuba i nuspojave. Što je fiksni ortodontski aparatić? Cilj ortodontske terapije je ispraviti zbijene, iskrivljene, neizrasle ili izbočene zube. Osobe koje primaju ortodontsku terapiju su najčešće adolescenti i odrasli. Fiksni ortodontski aparatići sastoje se od bravica...

Je li promjena unosa masti u prehrani korisna ili štetna za osobe sa žučnim kamencima? Ključne poruke – Dokazi o učincima unosa masti hranom za osobe sa žučnim kamencima su nejasni. Što su žučni kamenci? Žučni kamenci, također poznati kao kolelitijaza, su naslage iz probavne tekućine koje se sastoje od očvrslih tvari kao što su kolesterol i žučni pigmenti koji se nalaze u žuči (tekućina koja razgrađuje masti, a stvara je i otpušta jetra i pohranjuje se u žučnom mjehuru). Kolesterol (tvar slična masti) cirkulira krvlju i sve stanice u tijelu sadrže kolesterol. Previše kolesterola može...

Je li LipiFlow učinkovitiji od drugih oblika liječenja bolesti suhog oka? Ključne poruke • LipiFlow djeluje slično drugim uobičajenim načinima liječenja bolesti suhog oka u pogledu znakova i simptoma, ali dokazi za to su vrlo nesigurni. • Čini se da LipiFlow nije uzrokovao nikakve nuspojave. Što je bolest suhog oka? Bolest suhog oka uobičajeno je stanje s nekoliko čimbenika rizika, uključujući dob bolesnika, spol, rasu, hormonsku neravnotežu, korištenje digitalnih uređaja i disfunkciju Meibomove žlijezde. Disfunkcija Meibomove žlijezde je primarni uzrok bolesti suhog oka. Ove žlijezde u...

Specifications: Permanent – Full Time
Salary:  £42,000 per Annum  
Location: (Remote – Flexible) UK, Germany, Denmark. Candidates anywhere from the world will be considered; however, Cochrane’s Central Executive Team is only able to offer consultancy contracts outside these countries.
Directorate: CEOO
Closing date: 18 February 2024
 
Cochrane is an international charity. For 30 years we have responded to the challenge of making vast amounts of research evidence useful for informing decisions about health. We do this by synthesising research findings and our work has been recognised as the international gold standard for high quality, trusted information.

Cochrane's strength is in its collaborative, global community. We have 110,000+ members and supporters around the world. Though we are spread out across the globe, our shared passion for health evidence unites us. Our Central Executive Team supports this work and is divided into four directorates: Evidence Production and Methods, Publishing and Technology, Development, and Finance and Corporate Services.

As a Manager within Cochrane’s Central Executive Team, you will support Cochrane’s Geographic Groups, Networks, and Fields, play a pivotal role in supporting sustainable development, coordinating activities, and enhancing accountability frameworks. This position focuses on fostering collaboration, overseeing communication, and promoting growth within Cochrane’s global networks.

Don’t have every single qualification? We know that some people are less likely to apply for a job unless they are a perfect match. At Cochrane, we’re not looking for “perfect matches.” We’re looking to welcome people to our diverse, inclusive, and passionate workplace. So, if you’re excited about this role but don’t have every single qualification, we encourage you to apply anyway. Whether it’s this role or another one, you may be just the right candidate.

Our organization is built on four core values: Collaboration: Underpins everything we do, locally and globally. Relevant: The right evidence at the right time in the right format. Integrity: Independent and transparent. Quality: Reviewing and improving what we do, maintaining rigour and trust.  

You can expect: 

• An opportunity to truly impact health globally.  
• A flexible work environment  
• A comprehensive onboarding experiences.
• An environment where people feel welcome, heard, and included, regardless of their differences.

Cochrane welcomes applications from a wide range of perspectives, experiences, locations, and backgrounds; diversity, equity and inclusion are key to our values.

How to apply

• For further information on the role and how to apply,
• The deadline to receive your application is 18th Feb, 2024.
• The supporting statement should indicate why you are applying for the post, and how far you meet the requirements, using specific examples. 
• Read our Recruitment Privacy Statement

Friday, February 2, 2024 Category: Jobs

Friday, February 2, 2024

Friday, February 2, 2024

Last week, Cochrane participated in the 154th session of the World Health Organization (WHO) Executive Board meeting in Geneva.

The Executive Board is composed of 34 technically qualified representatives from different Member States, elected for three-year terms. Every January, the Executive Board meets at WHO headquarters to discuss global public health priorities for the year ahead and set the agenda for the World Health Assembly.

In addition to the Executive Board, all Member States and civil society organizations in official relations with WHO, such as Cochrane, are given the opportunity to contribute. This provided our delegation a great platform to advocate for evidence-based health policy. 

The session began with an opening statement by WHO Director-General. He highlighted the key achievements of the previous year, including the landmark decision to include life-changing treatments for multiple sclerosis drugs in the Essential Medicines List, which Cochrane Multiple Sclerosis and Rare Diseases of the CNS played a key role in.

WHO’s 14th General Programme of Work (GPW14) was a major focus of this year’s meeting. GPW14 is a medium-term strategy agreed by Member States and will defines the direction of WHO’s work (including on evidence-based health) for 2025-28, with the goal to promote, provide, and protect health. 

Emma Thompson, Cochrane’s Advocacy and Partnerships Lead, made a statement in front of Member States and WHO’s Director-General, speaking on behalf of Cochrane in applauding the draft GPW’s recognition of WHO’s science and evidence-based leadership, particularly highlighting the importance of high-quality evidence in health decision making. 

In addition to the official planned activities at the Executive Board meeting, Cochrane’s delegation used the opportunity to meet with several different WHO departments to discuss plans for Cochrane’s Scientific Strategy, which is currently in development, and opportunities for our next joint workplan.

Our delegation had many productive conversations with key individuals and teams on how Cochrane and WHO can continue to work together to address global public health priorities in the coming years. Supported by our years of relationship building, collaboration and advocacy, we held meetings with many WHO teams, covering a wide range of portfolios including maternal, newborn and child health; essential medicines; malaria, tropical diseases; nutrition; clinical trials; guidelines; health emergencies; and science. 

Another key highlight of the week was a meeting between Cochrane’s Editor-in-Chief, Dr Karla Soares-Weiser, and the Director of the Pan American Health Organization (PAHO), Dr Jarbas Barbosa and Dr Rhonda Sealey-Thomas, PAHO Assistant Director. During the meeting, they discussed collaboration between Cochrane and PAHO, which is underpinned by a new memorandum of understanding and Dr Soares-Weiser highlighted Cochrane’s enthusiasm for the formalisation of this partnership.

• Find out more about the 154th session of the Executive Board

Thursday, February 1, 2024 Category: The difference we make

Today marks the official opening of registration for attendance at the second Global Evidence Summit (GES) 2024. Organized by the world’s leading organizations in evidence synthesis and evidence-based practice, including Cochrane, JBI, Guidelines International Network (GIN), and The Campbell Collaboration, the summit is set to take place in the historical city of Prague, Czech Republic, from 10 to 13 September 2024, with satellite meetings on 9 September 2024.

The GES is intended as a multi-disciplinary and cross-cultural event to exchange ideas about how we best produce, summarise and disseminate evidence to inform policy and practice, and using that evidence to improve people’s lives across the world. The summit will feature plenary keynote speakers, special sessions with panel experts, and traditional conference elements like posters and oral presentations. There will also be a robust social program to make sure there are plenty of opportunities to network and have conversations across sectors, such as health, education, social justice, the environment, and climate change. The programme domains include:

• Sustainable development agenda
• Research integrity & making evidence accessible
• Power of synergy in evidence & synthesis products
• Evidence translation & implementation
• Advocating for greater evidence communication & use of evidence
• From global evidence to local impact 

Miloslav Klugar, Chair of the Scientific and Local Organising Committee, extends a warm welcome:

“On behalf of our organising partners, I invite you all to join us for the eagerly anticipated 2nd Global Evidence Summit. You belong at GES! It’s a unique gathering of research and scientists, policymakers and managers but also students, consumers and activities, and patients and caregivers. This is a unique opportunity for people across the globe to get involved in evidence-based practice, with a shared mission to provide a platform to discuss critical issues across different sectors, including health, education, social justice, the environment and climate change.”  

Catherine Spencer, Cochrane's CEO, emphasizing the significance of the GES in fostering synergies and knowledge sharing within the global evidence community:

" I encourage the Cochrane Community to take advantage of Early Bird Registration for the 2nd Global Evidence Summit. Your participation will not only enrich your knowledge but also contribute to a global movement towards impactful, evidence-informed decision-making. Let's unite for #GES2024 and contribute to advancing evidence-based practice globally! We look forward to seeing you there!"

 

Early-bird registration is now open until 13 June. Standard registration is open until 14 August with late/onsite registration available. We also offer discounts to those from low-income economies as well as patients/consumers and students.

• Visit the GES website
• Learn more about registration
• Registration form

Thursday, February 29, 2024

Thursday, February 1, 2024

Neimunosupresivno liječenje IgA nefropatije Ključne poruke Liječenje inhibicijom renin-angiotenzinskog sustava (RAS), odnosno inhibitorima angiotenzin-konvertirajućeg enzima ili blokatorima angiotenzinskih receptora, najčešća je prva neimunosupresivna linija terapije koja se koristi za liječenje bolesnika s IgA nefropatijom (IgAN). Uloga drugih neimunosupresivnih tretmana u upravljanju IgAN-om je nejasna i zahtijeva daljnja klinička istraživanja. Zašto liječiti IgA nefropatiju neimunosupresivnim terapijama? IgAN je jedna od najčešćih bolesti bubrega koja dovodi do smanjene funkcije bubrega i...

Wednesday, January 31, 2024

Wednesday, January 31, 2024

Monday, January 29, 2024